BCG and Eczema Prevention: The MIS BAIR One-Year and Five-Year Findings Are Not the Same Result
DOCTOR’S NOTES · ECZEMA EVIDENCE
Research on a tuberculosis vaccine and eczema prevention can sound surprising. The useful question is not whether families should independently seek BCG for a rash, but what a randomized prevention study found at different ages and how that relates to current vaccine guidance.
The first-year comparison had uncertainty
The original MIS BAIR report randomized 1,272 infants in Australia to neonatal BCG-Denmark or no BCG. First-year eczema incidence was 32.2% versus 36.6%; adjusted risk difference −4.3 percentage points, 95% confidence interval −9.9 to +1.3. That interval included no difference. A high-risk subgroup with two atopic parents showed a more favorable estimate.
The later follow-up asked about cumulative incidence
The five-year follow-up, published in 2025, reported cumulative eczema incidence of 37.1% versus 45.3%, adjusted difference −8.2 percentage points, 95% confidence interval −14.1 to −2.2. The analysis adjusted for randomization stratification factors and used multiple imputation for missing data. The report found no evidence of subgroup interaction.
| Time point | Question answered |
|---|---|
| 12 months | Whether eczema had occurred in the first year. |
| Five years | Whether eczema had occurred by that age. |
| Neither result | Whether BCG treats an existing eczema flare. |
Cumulative incidence is not current rash prevalence
A child can have developed eczema earlier and be clear at a later visit. Counting whether eczema ever occurred during follow-up is therefore different from counting who has visible lesions on one day. The changing results do not justify silently switching between those definitions in a caption.
The adjusted absolute difference is also different from a relative reduction. Both can describe a study, but the denominator and period must remain attached. A subgroup’s apparently larger estimate does not prove that the intervention works differently in that subgroup when the interaction analysis does not establish such a difference.
A prevention signal is not a vaccination recommendation
CDC’s current BCG guidance describes a tuberculosis vaccine that is not generally used in the United States. It discusses specific circumstances for consideration with TB experts and notes that BCG can affect TB skin testing. These prevention-study findings do not replace that clinical and public-health framework.
Do not delay routine recommended vaccinations, seek BCG as a self-directed eczema intervention or interpret lack of neonatal BCG as a cause of a child’s eczema. The trial did not test treatment of established disease, and differences in setting, vaccine strain and follow-up matter.
What parents can discuss
If a prevention claim appears in an advertisement or social post, ask which age, outcome and population it describes. Bring the actual paper to the pediatric clinician when discussing family risk. A child who already has persistent symptoms needs an individualized skin-care and treatment plan regardless of how a prevention trial was conducted.
Why one-year and two-year supplement-prevention findings also need to remain separate
Where moisture care fits
Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not tested in the research discussed here. These findings do not establish pediatric efficacy or infant suitability for #003; ask a child’s clinician about an appropriate moisturizer.
Continue with a related question
- How to Read an Eczema Study Without Getting Misled by Percentages
- Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
- What Is SCORAD? Understanding an Eczema Severity Score
Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational content does not diagnose an individual or imply independent medical review. Cited researchers and institutions do not endorse #003. Image is an AI-created editorial product illustration, not a patient photograph or clinical result.